AI-powered device to identify low LV ejection fraction gains FDA 510(k) clearance

Related Articles
Pfizer, Anumana team up to develop AI algorithm for cardiac amyloidosis detection
Mobi Health News: Anumana, a joint venture between EHR data company nference and the Mayo Clinic, entered into a multiyear partnership with Pfizer to develop an AI-based tool for the…December 16, 2022
How Mayo Clinic is using AI to spot hidden heart conditions
Advisory Board: Mayo Clinic last month released a study suggesting that an artificial intelligence (AI) algorithm could be used to better diagnose a certain heart condition called low ejection fraction—one step…May 31, 2021
AI specialists ink deal with Pfizer to target cardiac amyloidosis
Cardiovascular Business: Anumana, a Massachusetts-based healthcare technology company focused on artificial intelligence (AI), has announced a new multi-year deal with Pfizer focused on improving the identification and diagnosis of cardiac…December 20, 2022
Migraine with aura identified as independent risk factor for A-fib
Medical Xpress: Patients with migraine with aura (MwA) have significantly higher artificial intelligence-enabled electrocardiogram (AI-ECG) atrial fibrillation (AF) prediction model output, according to a study from Mayo Clinic published online…August 03, 2022


